STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2918 by analyst upside · 2026-08-13
TEVA
Teva Pharmaceutical Industries Limited
Healthcare · Market Cap $43B · P/E 61.2x
ANALYST PRICE TARGET
+12.1%
implied upside to consensus target
Current Price $36.74
Consensus Target $41.2
Bull Target $50.0
Bear Target $33.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
6
Hold
0
Sell
0
52-Week Low $16.67
52-Week High $37.35
YTD Return +18.7%
FUNDAMENTALS
Market Cap $43B
P/E Ratio (TTM) 61.2x
Forward P/E 11.9x
EPS (TTM) $0.60
PEG Ratio 0.97
Dividend Yield N/A
Revenue (TTM) $17.3B
Profit Margin 4.1%
52-WEEK RANGE
52-Week Low $16.67
52-Week High $37.35
Current Price $36.74
Bear Target $33.0
Bull Target $50.0
● Now $36.74 ● Target $41.2
TRADING DATA
Avg Volume 5.8M
YTD Return +18.7%
Analyst Count 10
Consensus Buy
Upside to Target +12.1%
Last Updated 2026-08-13

ANALYST SUMMARY

Teva Pharmaceutical Industries Limited (TEVA) is currently trading at $36.74 with a Wall Street consensus price target of $41.2, implying potential upside of 12.1% over the next 12 months. 10 analysts currently cover TEVA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $50.0, while the most cautious has a target of $33.0.

TEVA operates in the Healthcare sector with a market capitalisation of $43B. The stock is up 18.7% year-to-date and is currently trading near the upper end of its 52-week range of $16.67 – $37.35.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TEVA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Overweight → Overweight 2026-05-06 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-04-30 43% win rate (7 calls)
UBS - Reiterated
Buy → Buy 2026-04-30 33% win rate (6 calls)
Piper Sandler reit
Overweight → Overweight 2026-04-30 14% win rate (7 calls)
Truist Securities - Reiterated
Buy → Buy 2026-04-30 Building track record
B of A Securities - Reiterated
Buy → Buy 2026-04-09 Building track record
Piper Sandler reit
Overweight → Overweight 2026-03-04 14% win rate (7 calls)
Truist Securities - Reiterated
Buy → Buy 2026-02-18 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
66
out of 100
Coverage depth
18/30
Consensus clarity
21/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →